Literature DB >> 32287598

I, 1.Viral causes of gastroenteritis.

Umesh D Parashar1, Roger I Glass1.   

Abstract

This chapter discusses the causative viral agents, pathophysiology, and immunology of gastroenteritis. Acute gastroenteritis is among the most common illnesses of humans and is caused by a variety of agents, including bacteria, viruses, parasites, toxins, and chemicals. The clinical spectrum ranges from asymptomatic or mild infection to severe dehydrating illness with a fatal outcome; the latter occurs primarily in young children and in the elderly. The chapter concludes with a discussion on the prevention and treatment of gastroenteritis. For the prevention of epidemic viral gastroenteritis, efforts need to be focused on caliciviruses. No specific antiviral therapy is recommended for childhood viral gastroenteritis, emphasizing the importance of distinguishing it from the selected forms of bacterial and parasitic gastroenteritis that require treatment. Other than pertinent epidemiologic information, certain clinical features of illness may provide etiologic clues, but they are not highly discriminating. Standard therapy of viral enteric infections relies on maintenance of adequate hydration and electrolyte balance. Oral rehydration therapy (ORT) is the main treatment.
Copyright © 2003 Published by Elsevier B.V.

Entities:  

Year:  2004        PMID: 32287598      PMCID: PMC7134077          DOI: 10.1016/S0168-7069(03)09002-5

Source DB:  PubMed          Journal:  Perspect Med Virol        ISSN: 0168-7069


  59 in total

Review 1.  Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries.

Authors:  J S Bresee; R I Glass; B Ivanoff; J R Gentsch
Journal:  Vaccine       Date:  1999-05-04       Impact factor: 3.641

2.  Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules.

Authors:  M A Miller; L McCann
Journal:  Health Econ       Date:  2000-01       Impact factor: 3.046

3.  Cost-effectiveness analysis of a rotavirus immunization program for the United States.

Authors:  A W Tucker; A C Haddix; J S Bresee; R C Holman; U D Parashar; R I Glass
Journal:  JAMA       Date:  1998-05-06       Impact factor: 56.272

4.  Sapporo virus: history and recent findings.

Authors:  S Chiba; S Nakata; K Numata-Kinoshita; S Honma
Journal:  J Infect Dis       Date:  2000-05       Impact factor: 5.226

5.  Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specific antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus.

Authors:  J J Gray; C Cunliffe; J Ball; D Y Graham; U Desselberger; M K Estes
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

Review 6.  Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials.

Authors:  H Szajewska; J Z Mrukowicz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2001-10       Impact factor: 2.839

7.  The diagnostic gap in diarrhoeal aetiology.

Authors:  T H Flewett; G M Beards; D W Brown; R C Sanders
Journal:  Ciba Found Symp       Date:  1987

8.  Gastroenteritis in sentinel general practices,The Netherlands.

Authors:  M A de Wit; M P Koopmans; L M Kortbeek; N J van Leeuwen; A I Bartelds; Y T van Duynhoven
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

9.  Rotavirus infection in infants as protection against subsequent infections.

Authors:  F R Velázquez; D O Matson; J J Calva; L Guerrero; A L Morrow; S Carter-Campbell; R I Glass; M K Estes; L K Pickering; G M Ruiz-Palacios
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

10.  Prevalence of enteric viruses in human immunodeficiency virus seropositive patients in Venezuela.

Authors:  G G González; F H Pujol; F Liprandi; L Deibis; J E Ludert
Journal:  J Med Virol       Date:  1998-08       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.